¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼­¿ï ±Ý°­È¦

±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 010-8584-0193  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 1Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼­¹Î¼®(¼­¿ïÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11
´ÙÀ½±Û 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
497 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 KYUNG HEE SHOULDER SYMPOSIUM : 2018-09-08 0 1,523 2018-08-22
496 ´ë±¸ °æºÏ´ëÇб³º´¿ø Á¦ 3Â÷ °³¿øÀǸ¦ À§ÇÑ ´ëÇѺÎÁ¤¸ÆÇÐȸ ¿¬¼ö±³À° : 2018-09-07 0 752 2018-08-22
495 °­¿ø ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø NAFLD(non-alcoholic fatty liver disease) and Cardiometabolic Syndrome [7th Gangwon Heart Seminar 2018] : 2018-09-07 0 924 2018-08-22
494 ÀüºÏ ÀüÁÖ ¿¹¼öº´¿ø ´ëÇÑÀçÈ°ÀÇÇÐȸ È£³²Á¦ÁÖÁöȸ ÀçÈ° ½ÉÆ÷Áö¾ö : 2018-09-07 0 1,041 2018-08-22
493 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 852 2018-08-22
492 ¼­¿ï 2018³â °³¿øÀǸ¦ À§ÇÑ °­µ¿°æÈñ´ëÇб³º´¿ø ¼ÒÈ­±âÁúȯ ¿¬¼ö°­Á : 2018-09-06 0 687 2018-08-22
491 Ãæ³² ´Ü±¹´ëÇб³º´¿ø 2018³â Á¦3Â÷ ´ëÇѺ´¸®ÇÐȸ ´ëÀü¤ýÃæûÁöȸ: ÃÖ½ÅÀÇÇÐÁ¤º¸ Ư°­ ¹× º´¸®ÇÐ Áõ·Ê ¹ßÇ¥ : 2018-09-06 0 775 2018-08-22
490 ´ë±¸ ´ëÇѽŻý¾ÆÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 997 2018-08-22
489 Àü³² Á¦257Â÷ ´ëÇѳ»°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Çмú´ëȸ : 2018-09-06 0 575 2018-08-22
488 °æ³² ´ëÇÑÇǺΰúÇÐȸ º£Ã¼Æ®º´ÀÇ ÃÖ½ÅÁö°ß¿¡ °üÇÏ¿© : 2018-09-06 0 718 2018-08-22
487 Ãæ³² °Ç¾ç´ëÇб³º´¿ø ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2018-09-06 0 900 2018-08-22
486 ´ë±¸ °è¸í´ëÇб³ µ¿»êÀÇ·á¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦234Â÷ °æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 746 2018-08-22
485 °æ±â °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ´ëÇѺñ´¢±â°úÇÐȸ 2018 Á¦ 3Â÷ ÀÎõ.°æ±âÁöȸ Áý´ãȸ : 2018-09-06 2 1,477 2018-08-22
484 °æ³² ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018³âµµ 3Â÷ ºÎ»ê¿ï»ê°æ³² ÈäºÎ¿Ü°ú Áý´ãȸ ¹× °­¿¬ : 2018-09-06 0 701 2018-08-22
483 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-06 0 533 2018-08-22
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷